- Home
- RCS vs IVA Comparison
RCS vs IVA Comparison
Compare RCS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- IVA
- Stock Information
- Founded
- RCS 1994
- IVA 2011
- Country
- RCS United States
- IVA France
- Employees
- RCS N/A
- IVA N/A
- Industry
- RCS Investment Managers
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- IVA Health Care
- Exchange
- RCS Nasdaq
- IVA Nasdaq
- Market Cap
- RCS 334.5M
- IVA 359.6M
- IPO Year
- RCS N/A
- IVA 2020
- Fundamental
- Price
- RCS $7.33
- IVA $5.45
- Analyst Decision
- RCS
- IVA Strong Buy
- Analyst Count
- RCS 0
- IVA 6
- Target Price
- RCS N/A
- IVA $15.33
- AVG Volume (30 Days)
- RCS 141.1K
- IVA 72.1K
- Earning Date
- RCS 01-01-0001
- IVA 09-26-2025
- Dividend Yield
- RCS 10.12%
- IVA N/A
- EPS Growth
- RCS N/A
- IVA N/A
- EPS
- RCS N/A
- IVA N/A
- Revenue
- RCS N/A
- IVA $14,591,573.00
- Revenue This Year
- RCS N/A
- IVA $80.35
- Revenue Next Year
- RCS N/A
- IVA N/A
- P/E Ratio
- RCS N/A
- IVA N/A
- Revenue Growth
- RCS N/A
- IVA N/A
- 52 Week Low
- RCS $4.51
- IVA $1.53
- 52 Week High
- RCS $6.31
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- RCS 70.39
- IVA 60.54
- Support Level
- RCS $7.16
- IVA $5.21
- Resistance Level
- RCS $7.22
- IVA $5.75
- Average True Range (ATR)
- RCS 0.05
- IVA 0.40
- MACD
- RCS 0.01
- IVA 0.04
- Stochastic Oscillator
- RCS 97.80
- IVA 55.80
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.